Core Viewpoint - China's service trade is expected to maintain steady growth in 2025, with a total import and export volume increasing by 7.4% year-on-year, and the structure of service trade continuously optimizing [1]. Group 1: Knowledge-Intensive Service Trade - Knowledge-intensive service trade is projected to grow, with imports and exports reaching 30,879.5 billion yuan, a year-on-year increase of 6.6% [1]. - The telecommunications, computer, and information services sectors are experiencing rapid growth in import and export rates [1]. - The surplus in knowledge-intensive services expanded by 1,581.7 billion yuan compared to the previous year [1]. Group 2: Technological Advancements - As China's enterprises enhance their R&D capabilities and technological levels, new competitive advantages are emerging in fields such as artificial intelligence, biomedicine, and high-end manufacturing [3]. - This advancement is driving the rapid growth of service exports related to intellectual property usage fees [3]. Group 3: Travel Service Trade - Travel service exports are maintaining high growth, with total imports and exports reaching 22,067 billion yuan in 2025, reflecting a year-on-year increase of 7.6% [6]. - Travel service exports have surged by 49.5% year-on-year, while imports have seen a modest increase of 1.4% [6].

Core Viewpoint - The rapid development of artificial intelligence and biomedicine is leading to unprecedented changes in the healthcare service industry [2][6]. IPO Details - Zhuozheng Medical Holdings Limited is set to be listed on the Hong Kong Stock Exchange on February 6, 2026, under the stock code "2677" [2]. - The company issued a total of 4,750,000 shares, raising a total of HKD 284 million, with a subscription rate of 2730.73 times for the public offering and 5.79 times for the international offering [2]. - Notable cornerstone investors include He Xiaopeng, CEO of Xiaopeng Motors, who subscribed for USD 1 million, and other tech companies with AI attributes [3]. Market Position and Growth - Zhuozheng Medical ranks first and second among private high-end comprehensive medical service institutions in terms of the number of cities covered and the number of paid patient visits in 2024 [9]. - The company has a strong reputation based on service quality, with high net promoter scores (NPS) of 81.1, 86.4, 85.9, and 87.6 from 2022 to 2025 [9]. Membership and Customer Retention - As of August 31, 2025, Zhuozheng Medical had 116,542 member accounts, with renewal rates increasing from 42% in 2022 to 67% in 2025 [11]. - The patient return rate also improved from 75.7% in 2022 to 82.7% in 2025, indicating strong customer loyalty [11]. Business Model - Zhuozheng Medical adopts a Costco-like model in the healthcare sector, focusing on a membership system and high-value services to drive growth [11][13]. - The company offers a range of services that cater to high-frequency health needs, allowing for longer customer retention periods and higher consumption frequency [13]. Financial Performance - Zhuozheng Medical achieved revenue growth from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [14]. - The gross profit also increased significantly, from CNY 44 million in 2022 to CNY 226 million in 2024, with a CAGR of 126.7% [14]. - The company turned profitable in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [14]. Investor Support - Zhuozheng Medical has received investments from notable firms such as Tencent, Matrix Partners, Tiantu Capital, and others, indicating strong institutional support [16][17]. - Investors believe that the company is well-positioned to meet the growing demand for high-quality healthcare services in China [17][18].

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses of about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show losses for 2025 [1] - The overall sales revenue and gross margin have slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments has led to a rise in credit impairment losses [1] - The depreciation of fixed assets has increased following the commissioning of a new vaccine workshop [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human and animal health businesses, leveraging its advanced biotechnology and production advantages in the human innovative drug sector [2] - The company aims to expedite the research and development and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]

Group 1 - The US and China are set to hold trade talks in Spain, focusing on unilateral tariffs and the "301 investigation," which could significantly impact market trends depending on the outcomes of these discussions [1] - The US has added several domestic entities to an export control blacklist, prompting China to initiate an anti-dumping investigation on related US-origin simulation chips, indicating ongoing pressure from the US while potentially boosting domestic chip production [1] - The People's Bank of China will conduct a 600 billion yuan reverse repurchase operation for six months, signaling a commitment to inject liquidity into the economy, which is expected to positively influence both the economy and the stock market [1] Group 2 - The State Council has emphasized the introduction of measures to promote private investment, particularly in new productive forces, emerging services, and new infrastructure, which is expected to create a positive outlook for short-term investments [2] - The acceleration of research and application of biopharmaceutical technologies has been highlighted, which could further enhance investment opportunities in the healthcare sector [2] - Regulatory authorities have taken serious action against financial fraud involving Dongfang Tong, which is anticipated to foster a fairer market environment and support long-term market stability [2]